

# Iain Macphee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8292964/publications.pdf>

Version: 2024-02-01

49  
papers

2,237  
citations

304368

22  
h-index

223531

46  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2384  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	1.0	374
2	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation, 2002, 74, 1486-1489.	0.5	283
3	The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation. American Journal of Transplantation, 2004, 4, 914-919.	2.6	238
4	Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians. Transplantation, 2005, 79, 499-502.	0.5	178
5	The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology, 1990, 70, 1-5.	2.0	175
6	Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?. American Journal of Transplantation, 2016, 16, 3443-3457.	2.6	92
7	Renohepatic crosstalk: does acute kidney injury cause liver dysfunction?. Nephrology Dialysis Transplantation, 2013, 28, 1634-1647.	0.4	75
8	European Society for Organ Transplantation Advisory Committee Recommendations on Generic Substitution of Immunosuppressive Drugs. Transplant International, 2011, 24, 1135-1141.	0.8	65
9	A Pharmacogenetic Strategy for Immunosuppression Based on the CYP3A5 Genotype. Transplantation, 2008, 85, 163-165.	0.5	49
10	Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study. American Journal of Transplantation, 2018, 18, 1370-1379.	2.6	47
11	Xenobiotic Metabolism: The Effect of Acute Kidney Injury on Non-Renal Drug Clearance and Hepatic Drug Metabolism. International Journal of Molecular Sciences, 2014, 15, 2538-2553.	1.8	43
12	The effects of acute renal failure on drug metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 11-23.	1.5	40
13	Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation. Therapeutic Drug Monitoring, 2011, 33, 178-184.	1.0	36
14	Pharmacogenetic biomarkers: cytochrome P450 3A5. Clinica Chimica Acta, 2012, 413, 1312-1317.	0.5	32
15	A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. British Journal of Clinical Pharmacology, 2013, 76, 425-431.	1.1	32
16	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clinical Transplantation, 2007, 21, 252-257.	0.8	31
17	CYP3A5 Genotype Had no Impact on Inpatient Variability of Tacrolimus Clearance in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2013, 35, 328-331.	1.0	30
18	The Pharmacogenetics of Immunosuppression for Organ Transplantation. Molecular Diagnosis and Therapy, 2003, 3, 291-301.	3.3	28

#	ARTICLE	IF	CITATIONS
19	BK Virus Nephropathy in Renal Transplant Patients in London. <i>Transplantation</i> , 2008, 85, 1008-1015.	0.5	27
20	Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2579-2586.	2.2	27
21	Tacrolimus Dose in Black Renal Transplant Recipients. <i>Transplantation</i> , 2007, 83, 997-999.	0.5	25
22	Black renal transplant recipients have poorer long-term graft survival than CYP3A5 expressers from other ethnic groups. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 628-634.	0.4	25
23	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2045-2058.	0.9	22
24	Cardiac and vascular changes with kidney transplantation. <i>Indian Journal of Nephrology</i> , 2016, 26, 1.	0.2	22
25	Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. <i>Intensive Care Medicine</i> , 2009, 35, 1271-1275.	3.9	20
26	Genotyping cytochrome P450 3A5 using the Light Cycler. <i>Annals of Clinical Biochemistry</i> , 2005, 42, 376-381.	0.8	19
27	Use of Pharmacogenetics to Optimize Immunosuppressive Therapy. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 261-264.	1.0	17
28	Page kidney: successful radiological management of acute renal failure. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1740-1740.	0.4	16
29	Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy. <i>EBioMedicine</i> , 2020, 58, 102899.	2.7	16
30	The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population. <i>American Journal of Transplantation</i> , 2019, 19, 2262-2273.	2.6	13
31	<i>Burkholderia pseudomallei</i> infection, or melioidosis, and nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 137-139.	0.4	11
32	Enlarged kidneys and acute renal failure why is a renal biopsy necessary for diagnosis and treatment?. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 401-403.	0.4	11
33	Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 761-771.	1.5	11
34	Individualized immunosuppression in transplant patients: potential role of pharmacogenetics. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 63.	0.4	11
35	Patient involvement in selection of immunosuppressive regimen following transplantation. <i>Patient Preference and Adherence</i> , 2014, 8, 1705.	0.8	11
36	CYP3A5 Genotype Does Not Influence the Blood Concentration of Tacrolimus Measured with the Abbott Immunoassay. <i>Clinical Chemistry</i> , 2005, 51, 2214-2215.	1.5	10

#	ARTICLE	IF	CITATIONS
37	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. Expert Opinion on Pharmacotherapy, 2005, 6, 2593-2605.	0.9	9
38	Generic Tacrolimus in Renal Transplantation. Transplantation, 2012, 93, e45-e46.	0.5	9
39	Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantation. Molecular and Cellular Endocrinology, 2018, 473, 205-216.	1.6	8
40	Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended-release tacrolimus preparation. Clinical and Translational Science, 2022, 15, 70-78.	1.5	8
41	UK Renal Registry 15th Annual Report: Chapter 3 Demographic and Biochemistry Profile of Kidney Transplant Recipients in the UK in 2011: National and Centre-Specific Analyses. Nephron Clinical Practice, 2013, 123, 55-80.	2.3	7
42	Do statins prevent acute kidney injury?. Expert Opinion on Drug Safety, 2015, 14, 1547-1561.	1.0	7
43	Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. Kidney International Reports, 2021, 6, 2803-2810.	0.4	7
44	Prophylaxis of cytomegalovirus infection in renal transplantation. Nephrology Dialysis Transplantation, 2001, 16, 2276-2279.	0.4	5
45	Blockade of OX40-ligand after initial triggering of the T helper 2 response inhibits mercuric chloride-induced autoimmunity. Immunology, 2006, 117, 402-408.	2.0	5
46	Paradoxical Response to Tacrolimus Assessed by Interleukin-2 Gene Expression. Transplantation Proceedings, 2006, 38, 3327-3330.	0.3	4
47	HLA Antibodyâ€“Incompatible Kidney Transplantation Between Jehovah's Witnessesâ€”A Case Report. Transplantation Proceedings, 2013, 45, 2069-2071.	0.3	3
48	Compromise of renal transplant blood flow by an arteriovenous graft. Nephrology Dialysis Transplantation, 2006, 21, 2644-2646.	0.4	2
49	Proteinuria in 3 sequential pregnancies following a fourth renal transplant. Journal of Nephrology, 2006, 19, 828-30.	0.9	1